N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=39 Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale
N/A N=33 Young Adult Eating Habits
Eating Behavior · Eating Habit
Primary: Change in Brain Response From Baseline to 2-weeks Post High UPF or 2 Weeks no UPF Diet — 0.02; 0.13 arbitrary units
Phase 2 N=30 Topiramate in Adolescents With Severe Obesity
Obesity, Morbid · Obesity · Weight Loss
Primary: Percent Change From Baseline in Body Mass Index at 28-Weeks — -2.74; -0.85 % change BMI
Phase 2 N=200 Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
Diabetes Mellitus · Hypertension · Metabolic Disease
Primary: Change in BMI Standard Deviation Score — -0.12; -0.06 Standard Deviation Score — p=0.007
N/A N=20 Protection Against Insulin Resistance in Obesity
Obesity · Insulin Resistance
Primary: Insulin Sensitivity — 273; 817 nmol/kg FFM/min /(µU/mL Insulin)
N/A N=30 Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
Phase 2 N=26 Exenatide in Extreme Pediatric Obesity
Obesity
Primary: Percent Change From Baseline in Body Mass Index at 3-months — -2.9; -0.15 percentage of change in BMI
N/A N=42 Teaching Obesity Treatment Options to Adult Learners Trial
Obesity · Patient Education · Weight Loss
Primary: Recruitment — 42 Participants
N/A N=314 Reducing Cardiometabolic Risk and Promoting Functional Health in Older Adults With Obesity and Prediabetes
Obesity · PreDiabetes · Aging
Primary: Change in Bodyweight — -7.4; -6.1 percentage of bodyweight change — p=0.196
N/A N=47 Healthy Bodies, Healthy Kids
Child Mental Disorders · Obesity · Metabolic Syndrome
Primary: DEXA-measured Adiposity — 0.76; -0.43; -2.79 kilograms — p=0.01
Phase 2 N=66 Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity
Severe Obesity
Primary: Body Mass Index — 10.1; 4.6 percentage (body mass index)
N/A N=50 Bariatric Surgery for Morbid Obesity
Obesity · Morbid Obesity
Primary: Size of Adipocytes — 73.4; 99.0; 103.0 µm
N/A N=25 Health Literacy and Obesogenic Behaviors
Obesity, Adolescent · Health Behavior · Health Knowledge, Attitudes, Practice
Primary: Improvement in Participants' Healthy Eating Behaviors as Assessed by the Dietary Screener Questionnaire and the National Youth Physical Activity and Nutrition Study — 3…
Phase 2 N=20 Study to Evaluate ARD-101 in Adults With Obesity
Obesity
Primary: Relative Change in Body Weight (%) — -0.33; 0.38 Percentage of body weight change
N/A N=28 Increased Monitoring of Physical Activity and Calories With Technology
Weight Change, Body · Behavior, Health · Obesity, Childhood
Primary: BMI Percentile — 98.46; 99.37 BMI percentile for age and sex
N/A N=28 Relative Sarcopenia and Cardiometabolic Risk in Young Adults With Obesity
Overweight and Obesity · Insulin Resistance
Primary: Percent Change in Serum Myostatin Levels From Pre- to 3 Hours Post-exercise — -6.9; 8.5 % change in serum myostatin — p=0.303
N/A N=67 Novel Executive Function Training for Obesity
Overweight and Obesity
Primary: Feasibility as Measured by Attendance — 18; 18 Sessions
Phase 4 N=226 Obesity, Oral Contraception, and Ovarian Suppression
Ovarian Suppression
Primary: Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression. — 54; 28; 11; 12 Participants
N/A N=10 Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Change in Weight — -.5 kg — p=.07
N/A N=281 Maternal-Offspring Metabolics:Family Intervention Trial
Pregnancy · Weight Gain
Primary: Gestational Weight Gain (GWG) — 12; 10 kg — p=0.01
N/A N=80 Effects of Obesity Treatments on Food Preferences and Metabolism
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Energy Intake From Baseline — 500; 310; 482; 5 kcal
Phase 2 N=22 Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls
Obesity
Primary: Change in Visceral and Subcutaneous Abdominal Adipose Tissue Over 6 Months — 57; 799; -111; 3634 mm^2 — p=0.70
N/A N=222 Maintenance After Initiation of Nutrition TrAINing
Obesity
Primary: Weight — 99.2; 105.7 kilograms — p=.04
N/A N=50 Interactive Obesity Treatment Approach for Obesity Prevention in Adults With Early Serious Mental Illness: iOTA-SMI
Obesity · Overweight · Severe Mental Disorder
Primary: Body Mass Index — 43.1; 38.1; 40.3; 40.3 kg/m^2 — p=0.97
Phase 3 N=193 Individualized Obesity Pharmacotherapy
Obesity
Primary: Change in Total Body Weight — -7.7; -6.5 percent change
Phase 2 N=150 SMART Use of Medication for the Treatment of Adolescent Severe Obesity
Adolescent Obesity
Primary: Percent Change in Body Mass Index (BMI) — -9.62; -12.27; -4.53; -2.53 % change in body mass index (BMI)
N/A N=77 Study of Growth Hormone and Bone in Obesity
Obesity · Osteopenia
Primary: Bone Mineral Density — -0.015; -0.008 grams/cm^2
N/A N=45 Obesity, Sleep Apnea, and Insulin Resistance
Insulin Sensitivity · Obstructive Sleep Apnea
Primary: Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo — 35.8; 34.4 AHI events/hour
Phase 2 N=12 GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children
Obesity, Morbid
Primary: Change in Body Mass Index (BMI) — -0.9; 0.84 change in kg/m^2